Cara Schiessler, APRN
Nurse Practitioner · Omaha, NENPI 1184959520
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Teleflex LLC accounts for 69.2% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2023 at $6,730 and has fallen 84.6% since, to $1,038 in 2025. Among nurse practitioner clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 233 payments — averaging $61.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$10K
- Urogen Pharma, Inc.$562
- Sumitomo Pharma America, Inc.$424
- Johnson & Johnson$401
- Palette Life Sciences, Inc.$322
- Myovant Sciences Inc.$291
- plus $2K from 32 others
What the payments were for
- Consulting fees$1,76712%
- Speaking & faculty fees$4,90234%
- Travel & lodging$1,1728%
- Food & beverage$6,57346%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 58 | $9,971 |
| Urogen Pharma, Inc. | 8 | $562 |
| Sumitomo Pharma America, Inc. | 43 | $424 |
| Johnson & Johnson | 18 | $401 |
| Palette Life Sciences, Inc. | 2 | $322 |
| Myovant Sciences Inc. | 11 | $291 |
| Merck | 11 | $275 |
| Boston Scientific | 6 | $231 |
| Janssen Scientific Affairs, LLC | 2 | $165 |
| Axonics, Inc. | 2 | $161 |
| Urovant Sciences Inc | 2 | $131 |
| Galvanize Therapeutics, Inc | 1 | $122 |
| Bayer | 6 | $117 |
| Accord Healthcare, Inc. | 4 | $96 |
| Dendreon Pharmaceuticals LLC | 5 | $94 |
| AbbVie(2 entities) | 6 | $88 |
| Antares Pharma, Inc. | 5 | $85 |
| SRS Medical Systems, Inc. | 1 | $84 |
| Endo Pharmaceuticals Inc. | 5 | $79 |
| EDAP Technomed Inc | 3 | $78 |
| Procept Biorobotics Corporation | 2 | $74 |
| 180 Medical, Inc. | 3 | $70 |
| Pfizer | 4 | $67 |
| Rochester Medical Corporation | 2 | $65 |
| Astellas Pharma US Inc | 4 | $63 |
| Tolmar, Inc. | 3 | $56 |
| Blue Earth Diagnostics | 2 | $34 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Tolmar Pharmaceuticals, Inc. | 2 | $31 |
| AstraZeneca | 2 | $27 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Progenics Pharmaceuticals, Inc. | 1 | $17 |
| Olympus America Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Endo USA, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Coloplast | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$8,712
- JELMYTO$452
- UroLift System$253
- Axonics$143
- AMS 700$138
- Erleada$125
- ALIYA SYSTEM$122
- KEYTRUDA$120
- ORGOVYX$120
- GEMTESA$119
How this compares
$14,413 in reported general payments places this provider in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 80 | $74,633 |
| GemtesaVibegron | 34 | $26,875 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $2,417 |
| Tamsulosin Hcl | 171 | $2,109 |
| Testosterone | 12 | $1,835 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 81 | $1,340 |
| Oxybutynin Chloride ErOxybutynin Chloride | 82 | $1,291 |
| Doxycycline Hyclate | 100 | $1,234 |
| Cefdinir | 68 | $1,005 |
| Tetracycline Hcl | 19 | $901 |
| Cefadroxil | 138 | $812 |
| Finasteride | 60 | $716 |
| Solifenacin Succinate | 33 | $715 |
| Testosterone Cypionate | 23 | $509 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 99 | $378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $63 | $74,63380 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $424 | $26,87534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Omaha
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Amanda GuggenmosOmaha$23K
- Amy YagerOmaha$15K
- Lindsay OneilOmaha$13K
- Beverly EverittOmaha$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.